[CAS NO. 155179-21-8] Vanicoside B

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [155179-21-8]

Catalog

HY-N9561

Brand

MCE

CAS

155179-21-8

DESCRIPTION [155179-21-8]

Overview

MDL	-
Molecular Weight	956.89
Molecular Formula	C49H48O20
SMILES	OC(C=C1)=CC=C1/C=C/C(OC[C@@]2([C@H]([C@@H]([C@H](O2)COC(/C=C/C3=CC=C(C=C3)O)=O)O)OC(/C=C/C4=CC=C(C=C4)O)=O)O[C@H]5O[C@@H]([C@H]([C@@H]([C@H]5O)O)O)COC(/C=C/C6=CC(OC)=C(C=C6)O)=O)=O

For research use only. We do not sell to patients.

Summary

Vanicoside B is a phenylpropanoyl sucrose derivative, can be isolated from the herb Persicaria dissitiflora . Vanicoside B targets cyclin-dependent kinase 8 ( CDK8 ) and exhibits anti-tumor activity. The potential mechanism is Vanicoside B blocks CDK8 -mediated signaling pathways and decreases the expression of epithelial-mesenchymal transition proteins, so that it leads to cell cycle arrest and apoptosis ^[1] ^[2] .

IC50 & Target

CDK3

STAT3

In Vitro

Vanicoside B (2.5-20 μM; 72 h) shows antiproliferative activity against a panel of cancer cell lines in triple-negative breast cancer (TNBC) MDA-MB-231 cells and HCC38 cells ^[1] .
Vanicoside B (2.5-20 μM; 72 h, 14 d, and 72 h, respectively) inhibits cell viability, colony formation, and disturbs cell cycle distribution in TNBC cells ^[1] .
Vanicoside B (2.5-10 μM; 48 h) decreased p-STAT1, p-STAT3, and p-S6 protein level, and induces apoptosis by regulating the Skp2-p27 axis in TNBC cells ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis ^[1]

Cell Line:	MDA-MB-231 cells and HCC38 cells
Concentration:	0, 2.5, 5, 10 μM
Incubation Time:	48 hours
Result:	Increased cleaved PARP, and p27 protein expressions, but decreased Skp2 protein level. Suppressed CDK8 target genes and the expression of EMT-associated proteins. Suppressed the expression of the cell proliferation marker Ki-67 in tumor tissues, also significantly suppressed the expressions of p-STAT1 (S727) and AXL.

Cell Cycle Analysis ^[1]

Cell Line:	MDA-MB-231 cells and HCC38 cells
Concentration:	0, 2.5, 5, 10 μM
Incubation Time:	72 hours
Result:	Inhibited cell cycle at sub-G1 phase.

In Vivo

Vanicoside B (5 mg/kg and 20 mg/kg; i.p.; 3 times per week for 4 weeks) inhibits tumor growth in xenografted mouse models with MDAMB-231 cells ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	MDA-MB-231 cell-implanted xenograft mouse model ^[1]
Dosage:	5 mg/kg, 20 mg/kg
Administration:	Intraperitoneal injection; 3 times per week over 4 weeks
Result:	Significantly reduced tumor volumes at 5 mg/kg and 20 mg/kg by 53.85% and 65.72%, respectively.

Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

References

Synonyms

α-D-Glucopyranoside, 1,3,6-tris-O-[(2E)-3-(4-hydroxyphenyl)-1-oxo-2-propen-1-yl]-β-D-fructofuranosyl, 6-[(2E)-3-(4-hydroxy-3-methoxyphenyl)-2-propenoate]

α-D-Glucopyranoside, 1,3,6-tris-O-[3-(4-hydroxyphenyl)-1-oxo-2-propenyl]-β-D-fructofuranosyl, 6-[3-(4-hydroxy-3-methoxyphenyl)-2-propenoate], [1[1(E),3(E),6(E)],6(E)]-

α-D-Glucopyranoside, 1,3,6-tris-O-[(2E)-3-(4-hydroxyphenyl)-1-oxo-2-propenyl]-β-D-fructofuranosyl, 6-[(2E)-3-(4-hydroxy-3-methoxyphenyl)-2-propenoate]

Vanicoside B